Super-resolution Clinical Brain Ultrasound

NCT05785598 | Completed

• 1 other identifier: APHP221331
• Study Type: observational
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Transcranial Doppler ultrasonography with injection of contrast agent (intravenously to enhance the ultrasound signal) is a non-invasive technique that has been used for years to study intracranial vessels that constitute the polygon of Willis. However, this technique does not allow good visualization of small vessels, such as perforating arteries. Ultrasound localization microscopy (ULM) is based on the principle of localizing injected microbubbles in order to follow their movement to map the microvascular structure. The concentration of these microbubbles must remain low (in contrast to its classical use in Doppler ultrasound) in order to isolate and localize them. By using the same images as those performed in clinical routine by Doppler ultrasound and by processing the data offline, ULM would increase the resolution by a factor of 10 allowing potential observation of perforating arteries.

Conditions

Ischemic Stroke; Moya Moya Disease

Keywords

Ischemic stroke; Moya-Moya; Super-Resolved Ultrasound; Ultrasonore microscopy; Perforating arteries

Outcome Measures

Primary Outcomes (1)

• To compare the number of perforating arteries detected by ULM with the number of perforating arteries detected on TOF MRI.

  density of perforating arteries that start from the middle cerebral artery. The unit of measurement will be a count of bubbles tracked by ULM in each pixel of the image.

  During the ULM analyse

Secondary Outcomes (2)

• To compare the number of perforating arteries detected by ULM with the number of perforating arteries detected by the standard EDTC.

  During the ULM analyse

• To compare the number of perforating arteries detected by ULM with the number of perforating arteries detected by arteriography in the detection of perforating arteries in patients with Moya Moya disease or syndrome.

  During the ULM analyse

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Two groups of patients who benefit from a standard transcranial ultrasound with injection of contrast product (Sonovue) as part of the standard care protocol. On one hand, patients with ischemic stroke, in the absence of middle cerebral artery occlusion and lacunar disease. In this group the perforating arteries are very fine and difficult to visualize by the usual techniques. On the other hand, patients with Moya-moya disease or syndrome. In these patients, there is an overdevelopment of the perforating arteries.

You may qualify if:

• Patients with ischemic stroke hospitalized in the neurology department of the Bichat Hospital in the absence of middle cerebral artery occlusion or lacunar disease.
• Patients followed in the neurology department of the Bichat/Lariboisière hospital with a diagnosis of Moya-Moya disease or syndrome
• Patient who has had a TST with contrast injection as part of his follow-up
• Patient who has had an MRI as part of his follow-up
• Presence of a temporal window that allows ultrasound insonification of the polygon circle of Willis.
• Age over 18 years.
• Patient not objecting to the analysis of their data

You may not qualify if:

• Patient not affiliated to French Social Security.
• Patient under guardianship or curatorship.
• Pregnant or breastfeeding patients

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• Centre National de la Recherche Scientifique, France: collaborator

Study Sites (1)

AP-HP, Bichat Hospital

Paris, Paris, 75010, France

Location

MeSH Terms

Conditions

Ischemic Stroke; Moyamoya Disease

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Carotid Artery Diseases; Cerebral Arterial Diseases; Intracranial Arterial Diseases; Arterial Occlusive Diseases

Study Officials

• Elena MESEGUER

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 14, 2023
• First Posted: March 27, 2023
• Study Start: March 30, 2023
• Primary Completion: March 30, 2024
• Study Completion: March 30, 2024
• Last Updated: April 24, 2026

Record last verified: 2026-04

Locations

FR (1)